The authors concluded that the elevated levels of MMP2 and MMP9 in response to doxorubicin and the gene polymorphism identified to be correlated with AIC could be potentially used to assess the risk of AIC in breast cancer patients and indicate the use of prophylactic therapies at the later stages of AIC. This evidence concerns the gene MMP2 and breast carcinoma.